GeneThera Offered World Wide Rights to E.coli
Vaccine From the University of New Mexico
Posted 06 October 2008 @ 06:00 am EST
Source of Article: http://www.ibtimes.com/prnews/20081006/genethera.htm
WHEAT RIDGE, CO -- (Marketwire)
-- 10/06/08 -- GeneThera, Inc. (PINKSHEETS:
GTHR)announced today that it is in negotiations with the University of NewMexico for world wide development and distribution
rights to a vaccinedeveloped there that is designed
to significantly inhibit the carriage andshedding
of the E.coli bacteria in cattle.
According to University sources,
the vaccine is comprised of "LiveAttenuated
Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding ofEnterohemorrhagic Escherichia Coli in Cattle"
In the most recent case, the U.S. Agriculture Department, on August 11,said, "Omaha meat packing company Nebraska Beef Ltd
is recalling 1.2million pounds of beef because it may be contaminated with a particularlydangerous strain of E.coli."
According to the Associated Press, dated February 17, 2008, "The U.S.Department of Agriculture is ordering the recall of
143 million pounds offrozen beef from aCalifornia slaughterhouse. Officials say it's the
largest beef recall inthe United States,surpassing a 1999 ban of 35
million pounds of ready-to-eat meats. Therecall
will affect beef products dating to February 1st, 2006."
Commenting on the news, GeneThera Chairman Dr. Tony
Milici, MD, PhD stated,"I
look forward to finalizing the agreement with the University of NewMexico regarding the E.coli vaccine license rights. I believe this is agreat opportunity for GeneThera
to continue developing molecular tests andtherapeutics
to better detect and control the spread of E.coli 0157:H7.This
could have profound effects on increasing the safety of our meatsupply worldwide... not to mention the millions of
dollars it could savethe beef industry by reducing
occurrences of E.coli contamination."
If an agreement is reached between GeneThera and
it will mean GeneThera will have "exclusive
rights to make, use,and
sell" the vaccine on a world wide basis.
ABOUT GENETHERA, INC:
GeneThera, Inc. is a molecular biotechnology
company located in WheatRidge, CO.
The Company provides genetic diagnostic solutions for theveterinary
and agricultural industries with future plans to include thehealth-care
industry. The Company's proprietary diagnostic solution isbased
on a genetic expression system, GES, a protocol designed to functionon a highly automated Fluorogenic
PCR platform. This platform enablesGeneThera to
offer tests that are presently not available from othertechnologies.
The GES is designed for a host of individual diseases, thecurrent
priority being Mad Cow disease, Chronic Wasting Disease, E.Coli0157:H7 and Johne's disease, all diseases affecting cattle worldwide.
This press release contains forward-looking statements, which are madepursuant to the Safe-Harbor provisions of the Private
Securities LitigationReform Act of 1995. Words such
as "intends," "believes," and similarexpressions
reflecting something other than historical fact are intended toidentify forward-looking statements, but are not the
exclusive means ofidentifying such statements.
These forward-looking statements involve anumber of
risks and uncertainties, including the timely development andmarket
acceptance of products and technologies, the ability to secureadditional
sources of finance, the ability to reduce operating expenses,and other factors described in the Company's
filings with the Securitiesand Exchange Commission.
The actual results that the Company achieves maydiffer
materially from any forward-looking statement due to such risks anduncertainties. The Company undertakes no obligation to
revise or update anyforward-looking statements in
order to reflect events or circumstances thatmay
arise after the date of this release.
Contact:GeneThera, Inc.Dr. Tony Milici303-463-6371http://www.genethera.net